How many new ALK-positive lung cancer treatments will be approved by end of 2024? | Categorical | | | 7 months ago | |
Will Lorbrena get FDA approval for first-line treatment by end of 2024? | Binary | | | 7 months ago | |
Will Lorbrena sales exceed $1 billion by end of 2024? | Binary | | | 7 months ago | |
What will be Lorbrena's market share among ALK-positive lung cancer treatments by end of 2024? | Categorical | | | 7 months ago | |
What will be Pfizer's quarterly revenue growth in Q4 2024? | Categorical | | | 7 months ago | |
Pfizer's annual revenue growth rate for fiscal year 2024? | Categorical | | | 7 months ago | |
FDA approval of Lorbrena for broader use by end of 2024? | Binary | | | 7 months ago | |
Lorbrena sales exceed $1 billion by end of 2024? | Binary | | | 7 months ago | |
Number of patients treated with Lorbrena by end of 2024? | Categorical | | | 7 months ago | |
Will Pfizer's stock price increase by 10% or more by end of Q3 2024? | Binary | | | 7 months ago | |
Lorbrena market share among ALK-positive advanced NSCLC treatments by end of 2024? | Categorical | | | 7 months ago | |
Pfizer stock price increases by more than 10% by June 30, 2024? | Binary | | | 7 months ago | |
